Since CD47 mAbs activate the phagocytosis of macrophages, CD47 mAb therapy should be avoided in patients with hematological malignancy-associated hemophagocytic lymphohistiocytosis and monocyte/macrophage-related malignancies. This evidence concerns the gene CD47 and hematologic disorder.